Abstract
Background
Several studies have associated elevated liver enzymes (LFTs), obesity, and type 2 diabetes (T2DM), and a link has been established between insulin resistance (IR) and elevated ferritin concentrations. We examined the relationship between LFTs, ferritin, and IR in morbid obese subjects and the effect of weight loss after bariatric surgery.
Methods
We measured liver enzymes, ferritin, insulin resistance, and glucose tolerance (by OGTT) in 159 morbid obese subjects (BMI = 44.4 ± 0.4 kg/m2) at baseline, 6 months and 1 year after laparoscopic-adjustable-gastric banding (LAGB). Subjects were divided in two groups: increased LFTs (ALT > 30; AST/ALT < 1) vs. normal LFTs.
Results
A large proportion of morbid obese subjects had increased LFTs (44%) which were associated with increased IR and ferritin, suggesting potential liver disease. A majority of the morbidly obese with increased LFTs, IGT, and T2DM, were male and had almost double ferritin concentrations, strongly correlated with ALT (r = 0.43, p < 0.0001). Both ferritin and ALT correlated with waist circumference and IR. One year after, LAGB glucose tolerance improved, LFTs and IR were reduced; ferritin did not change significantly, but was still correlated with IR.
Conclusions
Ferritin may be an additional useful marker for more severe hepatic IR.
Similar content being viewed by others
References
Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med. 2007;24:430–5.
Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care. 2005;28:1757–62.
Haynes P, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis. 2004;8:535–47, viii.
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.
Haap M, Fritsche A, Mensing HJ, et al. Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people. Ann Intern Med. 2003;139:869–71.
Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.
Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513–7.
Knobler H, Schattner A, Zhornicki T, et al. Fatty liver—an additional and treatable feature of the insulin resistance syndrome. QJM. 1999;92:73–9.
Hansen EN, Torquati A and Abumrad NN. Results of bariatric surgery. Annu Rev Nutr. 2006;26:481–511.
Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222–6.
Tuomainen TP, Loft S, Nyyssonen K, et al. Body iron is a contributor to oxidative damage of DNA. Free Radic Res. 2007;41:324–8.
Forouhi NG, Harding AH, Allison M, et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia. 2007;50:949–56.
Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179–87.
Machado M, Cortez-Pinto H. NASH, insulin resistance and iron. Liver Int. 2006;26:1159–62.
Pontiroli AE, Folli F, Paganelli M, et al. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care. 2005;28:2703–9.
Pontiroli AE, Pizzocri P, Librenti MC, et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab. 2002;87:3555–61.
Pontiroli AE, Pizzocri P, Paroni R, et al. Sympathetic overactivity, endothelial dysfunction, inflammation, and metabolic abnormalities cluster in grade III (World Health Organization) obesity: reversal through sustained weight loss obtained with laparoscopic adjustable gastric banding. Diabetes Care. 2006;29:2735–8.
Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001;24:539–48.
Matsuda M and DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70.
Muniyappa R, Lee S, Chen H, et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15–26.
Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.
Home PD and Pacini G. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. Diabetes Obes Metab. 2007.
DeFronzo RA, Ferrannini E and Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38:387–95.
Sindelar DK, Chu CA, Venson P, et al. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes. 1998;47:523–9.
Wyatt SB, Winters KP and Dubbert PM. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci. 2006;331:166–74.
Hanley AJ, Wagenknecht LE, Festa A, et al. Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2007;30:1819–27.
Schindhelm RK, Diamant M, Dekker JM, et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22:437–43.
Vari IS, Balkau B, Kettaneh A, et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2007;30:1795–801.
Zacharski LR, Ornstein DL, Woloshin S, et al. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J. 2000;140:98–104.
Moirand R, Mortaji A, Loreal O, et al. A new syndrome of liver iron overload with normal transferrin saturation. Lancet. 1997;349:95–7.
Ferrannini E. Insulin resistance, iron, and the liver. Lancet. 2000;355:2181–2.
Tuomainen TP, Diczfalusy U, Kaikkonen J, et al. Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic Biol Med. 2003;35:922–8.
Wolff SP. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull. 1993;49:642–52.
Acknowledgments
We acknowledge the expert technical assistance of Roberta Petz, Emma Buzzigoli, Emma Di Gregorio, and Demetrio Ciociaro.
Sources of Funding
The study has been partially supported by startup funds from the University of Texas Health Science Center (Franco Folli), funds from the Italian National Research Council (Amalia Gastaldelli) and MURST (Antonio Pontiroli).
Disclosures
There are no conflicts of interest for this paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gastaldelli, A., Perego, L., Paganelli, M. et al. Elevated Concentrations of Liver Enzymes and Ferritin Identify a New Phenotype of Insulin Resistance: Effect of Weight Loss After Gastric Banding. OBES SURG 19, 80–86 (2009). https://doi.org/10.1007/s11695-008-9690-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-008-9690-9